saxenda glp-1 diabetes market impact Agonists Weight Loss Drugs Report, 2025-2030 GLP-1 Agonists Market Exclusive Research

Wegovy is FDA-approved to assist with chronic weight management in adults with obesity or adults with an overweight body mass index and an additional metabolic comorbidity

"GAD65 autoantibody characteristics inpatients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies." (2018)

If weight loss has slowed or stopped, common causes include: not being in a calorie deficit despite reduced appetite, hitting a natural weight loss plateau, needing a higher dose tier, or insufficient time at the current dose

Ventral tegmental area GABA projections pause accumbal cholinergic interneurons to enhance associative learning